How Hedge Funds Won Big on an Obscure Drugmaker

It had been an anemic year for hedge funds that trade biotech stocks, thanks in part to moves by the Trump administration. A little-known French drugmaker provided a shot in the arm.

The PivotalPath Healthcare Index lost 5% in the first half of this year, despite a 4% gain in the PivotalPath Composite.